Evidence map›Paper›PMID 33525219›Full record

ArticleActa bio-medica : Atenei Parmensis2020

Clinical Outcome of Eosinophilia in Patients with COVID-19: A Controlled Study.

Arun Prabhakaran Nair, Ashraf Soliman, Muna A Al Masalamani, Vincenzo De Sanctis, Abdulqadir J Nashwan, Sreethish Sasi, Elrazi A Ali, Ola A Hassan, Fatima M Iqbal, Mohamed A Yassin

Open access · greenAbstract readMulticenter Study
In one paragraph

Article in Acta bio-medica : Atenei Parmensis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Immune Response Dynamics and Biomarkers in COVID-19 Patients.International journal of molecular sciences · 2024
    Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Arun Prabhakaran NairCommunicable Disease Center (CDC), Hamad Medical Corporation (HMC), Doha, Qatar. vdesanctis@libero.it.
Ashraf SolimanDepartment of Pediatrics. Hamad Medical Corporation (HMC), Doha, Qatar. vdesanctis@libero.it.
Muna A Al MasalamaniCommunicable Disease Center (CDC), Hamad Medical Corporation (HMC), Doha, Qatar. vdesanctis@libero.it.
Vincenzo De SanctisPediatric and Adolescent Outpatient Clinic, Quisisana Hospital, Ferrara, Italy. vdesanctis@libero.it.
Abdulqadir J NashwanHazm Mebaireek General Hospital (HMGH), Hamad Medical Corporation (HMC), Doha, Qatar. vdesanctis@libero.it.
Sreethish SasiDepartment of Internal Medicine, Hamad Medical Corporation (HMC), Doha, Qatar. vdesanctis@libero.it.
Elrazi A AliDepartment of Internal Medicine, Hamad Medical Corporation (HMC), Doha, Qatar. vdesanctis@libero.it.
Ola A HassanFamily Medicine, Medical Education, Hamad Medical Corporation (HMC), Doha, Qatar. vdesanctis@libero.it.
Fatima M IqbalCommunicable Disease Center (CDC), Hamad Medical Corporation (HMC), Doha, Qatar. vdesanctis@libero.it.
Mohamed A YassinDepartment of Haematology/Oncology, National Centre for Cancer Care and Research (NCCCR), Hamad Medical Corporation (HMC), Doha, Qatar. vdesanctis@libero.it.
Hamad Medical Corporation · QA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEosinophils can be considered as multifunctional leukocytes that contribute to various physiological and pathological processes depending on their location and activation status. There are emerging eosinophil-related considerations concerning COVID-19. Variable eosinophil counts have been reported during COVID-19. Whether these changes are related to the primary disease process or due to immunomodulation induced by the treatment has not yet been elucidated. AIM OF THE STUDY: To describe changes in the differential leukocyte counts including eosinophils, in a cohort of symptomatic patients with confirmed COVID-19 and to correlate these changes, if any, with the severity of the disease. PATIENTS AND

methodsWe recorded the clinical data, lab findings, including inflammatory markers and leukocyte and differential count, course of the disease and severity score in 314 confirmed symptomatic cases of COVID-19.

resultsLaboratory tests revealed that 28.7 % (n =86) had mild eosinophilia (eosinophil count > 500 <1,500/µL). Thirty-four patients (11.3%) had elevated absolute neutrophil count (ANC) (>8,000/µL), and 7 (2.3%) had decreased ANC (< 1,500/µl). Seven patients (2.3%) had lymphopenia (<1,000/µL) and 4 (4.67%) had lymphocytosis (> 4,000/µL). C-reactive protein (CRP) was elevated in 83 patients (27.6%). Chest X-Ray changes included: increased broncho vascular markings (38%), ground-glass opacity (GGO) pneumonitis (19.3%), lobar consolidation (5%), bronchopneumonia (8.3%), nodular opacity (1%), acute respiratory distress syndrome (ARDS) (2.3%), pleural effusion (1.0%) and other atypical findings (6.6%). Patients with eosinophilia had significantly lower CRP, and lower % of GGO, lobar and bronchopneumonia and ARDS in their chest images compared to patients without eosinophilia (p: <0.05). They also had a lower requirement for a hospital stay, ICU admission, mechanical ventilation, and oxygen supplementation versus patients without eosinophilia (p: <0.05). The eosinophils count was correlated negatively with the duration of ICU admission, mechanical ventilation, and oxygen supplementation and with CRP level (r: - 0.34, -0.32, -0.61 and - 0.39, respectively) (p: < 0.01).

conclusionsOur study reports a relatively high prevalence of eosinophilia in symptomatic COVID-19 positive patients. Patients with eosinophilia had a lower level of CRP, milder clinical course and better disease outcomes compared to those without eosinophilia. Our findings indicated a protective role of eosinophils in mitigating the severity of inflammatory diseases through an inhibitory mechanism, as evidenced by lower CRP. This protective role of eosinophils needs to be validated by further prospective studies.

Indexed as

AdultCOVID-19EosinophiliaEosinophilsFemaleHumansLeukocyte CountMaleMiddle AgedResearch DesignRetrospective StudiesSeverity of Illness Index

Identifiers

PMID33525219
PMCPMC7927494
OpenAlexW3126226775

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.